17 results on '"Montemurro, Filippo"'
Search Results
2. Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs).
- Author
-
Pisacane, Alberto, Cascardi, Eliano, Berrino, Enrico, Polidori, Alessio, Sarotto, Ivana, Casorzo, Laura, Panero, Mara, Boccaccio, Carla, Verginelli, Federica, Benvenuti, Silvia, Dellino, Miriam, Comoglio, Paolo, Montemurro, Filippo, Geuna, Elena, Marchiò, Caterina, and Sapino, Anna
- Abstract
The aim of this study is to envisage a streamlined pathological workup to rule out CUPs in patients presenting with MUOs. Sixty-four MUOs were classified using standard histopathology. Clinical data, immunocytochemical markers, and results of molecular analysis were recorded. MUOs were histologically subdivided in clear-cut carcinomas (40 adenocarcinomas, 11 squamous, and 3 neuroendocrine carcinomas) and unclear-carcinoma features (5 undifferentiated and 5 sarcomatoid tumors). Cytohistology of 7/40 adenocarcinomas suggested an early metastatic cancer per se. In 33/40 adenocarcinomas, CK7/CK20 expression pattern, gender, and metastasis sites influenced tissue-specific marker selection. In 23/40 adenocarcinomas, a "putative-immunophenotype" of tissue of origin addressed clinical-diagnostic examinations, identifying 9 early metastatic cancers. Cell lineage markers were used to confirm squamous and neuroendocrine differentiation. Pan-cytokeratins were used to confirm the epithelial nature of poorly differentiated tumors, followed by tissue and cell lineage markers, which identified one melanoma. In total, 47/64 MUOs (73.4%) were confirmed CUP. Molecular analysis, feasible in 37/47 CUPs (78.7%), had no diagnostic impact. Twenty CUP patients, mainly with squamous carcinomas and adenocarcinomas with putative-gynecologic-immunophenotypes, presented with only lymph node metastases and had longer median time to progression and overall survival (< 0.001), compared with patients with other metastatic patterns. We propose a simplified histology-driven workup which could efficiently rule out CUPs and identify early metastatic cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Surgical and Oncologic Outcomes of Robotic and Conventional Nipple-Sparing Mastectomy with Immediate Reconstruction: International Multicenter Pooled Data Analysis.
- Author
-
Park, Hyung Seok, Lee, Jeea, Lai, Hung-Wen, Park, Jung Mi, Ryu, Jai Min, Lee, Jeong Eon, Kim, Jee Ye, Marrazzo, Emilia, De Scalzi, Alessandra Margherita, Corso, Giovanni, Montemurro, Filippo, Gazzetta, Guglielmo, Pozzi, Giada, and Toesca, Antonio
- Abstract
Background: Robotic nipple-sparing mastectomy (RNSM) has been developed to reduce conspicuous scar and increase the quality of life in women. This study aimed to evaluate the surgical and oncologic outcomes of RNSM with immediate breast reconstruction (IBR) compared with conventional nipple-sparing mastectomy (CNSM). Patients and Methods: This international multicenter, pooled analysis of individual patient-level data enrolled a total of 755 procedures in 659 women (609 had breast cancer and 50 underwent risk-reducing mastectomy) who underwent nipple-sparing mastectomy with IBR. Surgical and oncologic outcomes, including 30-days postoperative (POD 30d) complication rate, nipple necrosis rate, grade of Clavien–Dindo classification, disease-free survival, and overall survival, were evaluated. Propensity score-matched analyses were performed to adjust for confounding factors. Results: The median age of both the RNSM and CNSM groups was 45 years. The RNSM group had lower body mass index (BMI) and a higher proportion of benign disease compared with the CNSM group. POD 30d complications and postoperative complication grade III rates were lower in the RNSM group than in the CNSM group (p < 0.05). The nipple necrosis rate was 2.2% and 7.8% for RNSM and CNSM, respectively (p = 0.002). After propensity score matching, significantly lower rates of POD 30d complications, nipple necrosis, and postoperative complication grade III occurred in the RNSM group than in the CNSM group (all p < 0.05). Oncologic outcomes were not significantly different between the two groups. Conclusion: RNSM can provide better cosmetic results with favorable surgical and oncologic outcomes for women with early breast cancer or BRCA mutation. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
4. Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer.
- Author
-
Puglisi, Fabio, Gerratana, Lorenzo, Lambertini, Matteo, Ceppi, Marcello, Boni, Luca, Montemurro, Filippo, Russo, Stefania, Bighin, Claudia, De Laurentiis, Michelino, Giuliano, Mario, Bisagni, Giancarlo, Durando, Antonio, Turletti, Anna, Garrone, Ornella, Ardizzoni, Andrea, Gamucci, Teresa, Colantuoni, Giuseppe, Gravina, Adriano, De Placido, Sabino, and Cognetti, Francesco
- Published
- 2021
- Full Text
- View/download PDF
5. Cancer of unknown primary stem-like cells model multi-organ metastasis and unveil liability to MEK inhibition.
- Author
-
Verginelli, Federica, Pisacane, Alberto, Gambardella, Gennaro, D'Ambrosio, Antonio, Candiello, Ermes, Ferrio, Marco, Panero, Mara, Casorzo, Laura, Benvenuti, Silvia, Cascardi, Eliano, Senetta, Rebecca, Geuna, Elena, Ballabio, Andrea, Montemurro, Filippo, Sapino, Anna, Comoglio, Paolo M., and Boccaccio, Carla
- Subjects
CANCER of unknown primary origin ,PRIMARY cell culture ,CANCER stem cells ,MITOGEN-activated protein kinases ,METASTASIS - Abstract
Cancers of unknown primary (CUPs), featuring metastatic dissemination in the absence of a primary tumor, are a biological enigma and a fatal disease. We propose that CUPs are a distinct, yet unrecognized, pathological entity originating from stem-like cells endowed with peculiar and shared properties. These cells can be isolated in vitro (agnospheres) and propagated in vivo by serial transplantation, displaying high tumorigenicity. After subcutaneous engraftment, agnospheres recapitulate the CUP phenotype, by spontaneously and quickly disseminating, and forming widespread established metastases. Regardless of different genetic backgrounds, agnospheres invariably display cell-autonomous proliferation and self-renewal, mostly relying on unrestrained activation of the MAP kinase/MYC axis, which confers sensitivity to MEK inhibitors in vitro and in vivo. Such sensitivity is associated with a transcriptomic signature predicting that more than 70% of CUP patients could be eligible to MEK inhibition. These data shed light on CUP biology and unveil an opportunity for therapeutic intervention. Cancer of unknown primary (CUP) is a mysterious malignancy featuring metastatic dissemination in the absence of a recognizable primary tumor. By characterizing CUP cancer stem cells we show that self-sustained long-term propagation and sensitivity to MEK inhibition are CUP common features. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
6. Primary tumor location predicts the site of local relapse after nipple-areola complex (NAC) sparing mastectomy.
- Author
-
Cont, Nicoletta, Maggiorotto, Furio, Martincich, Laura, Rivolin, Alessandro, Kubatzki, Franziska, Sgandurra, Paola, Marocco, Francesco, Magistris, Alessandra, Gatti, Marco, Balmativola, Davide, Montemurro, Filippo, Sapino, Anna, and Ponzone, Riccardo
- Abstract
Purpose: To assess the oncological safety of nipple-areola complex (NAC) sparing mastectomy in breast cancer patients. Methods: From 2010 to 2015, 518 breast cancer patients were submitted to NAC sparing mastectomy. Breast MRI and intraoperative assessment of the subareolar (SD) and proximal (ND) nipple ducts were performed to predict NAC involvement. Significant associations between pre- and postoperative variables with SD/ND involvement and with the risk of local recurrence were retrospectively investigated. Results: SD/ND were involved in 26.1% of the cases. Final pathology of SD/ND was predicted by tumor-NAC distance at MRI and intraoperative pathology with 75 and 93% accuracy, respectively. NAC involvement was more frequent in case of positive ND than positive SD (68.3 vs. 38.3%; p = 0.003). Fourteen (2.7%) local relapses developed over a mean follow-up of 33 months. Ki-67 ≥25% ( p = 0.002) and high tumor grade ( p = 0.027) correlated with local recurrence. Most relapses developed in the subcutaneous tissue of the quadrant where the primary tumor was located (12/14; 85.7%). No local relapses occurred in patients who received post-mastectomy radiotherapy as compared to patients who did not, although they had a higher rate of positive surgical margins (40.5 vs. 16.2%; p = 0.000). Conclusions: NAC involvement can be predicted by MRI and intraoperative pathology of ND/SD. Local recurrences after NAC sparing mastectomy almost invariably develop in the same quadrant where the primary tumor was located and in highly proliferative tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
7. Correction to: Real-world histopathological approach to malignancy of undefined primary origin (MUO) to diagnose cancers of unknown primary (CUPs).
- Author
-
Pisacane, Alberto, Cascardi, Eliano, Berrino, Enrico, Polidori, Alessio, Sarotto, Ivana, Casorzo, Laura, Panero, Mara, Boccaccio, Carla, Verginelli, Federica, Benvenuti, Silvia, Dellino, Miriam, Comoglio, Paolo, Montemurro, Filippo, Geuna, Elena, Marchiò, Caterina, and Sapino, Anna
- Published
- 2023
- Full Text
- View/download PDF
8. Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study.
- Author
-
Arpino, Grazia, Michelotti, Andrea, Truini, Mauro, Montemurro, Filippo, Russo, Stefania, Palumbo, Raffaella, Zamagni, Claudio, Latorre, Agnese, Bruzzese, Dario, Riccardi, Ferdinando, De Laurentiis, Michelino, Beano, Alessandra, Biganzoli, Laura, Zaniboni, Alberto, Laudadio, Lucio, Malagoli, Maria, Bilancia, Domenico, Schettini, Francesco, Giuliano, Mario, and Cazzaniga, Marina
- Subjects
BREAST cancer patients ,HER2 gene ,MEDICAL practice ,TRASTUZUMAB ,BREAST cancer treatment ,RANDOMIZED controlled trials ,ADJUVANT treatment of cancer - Abstract
Background: Several randomized clinical trials (RCTs) have demonstrated the efficacy of trastuzumab-based adjuvant therapy in HER2-positive breast cancer (BC). However, RCT patients may not invariably be representative of patients routinely seen in clinical practice (CP). To address this issue, we compared the clinical and tumor features of RCT and CP patients with HER2-positive BC. Patients and methods: From January to December 2012, 650 consecutive patients with HER2-positive early BC, treated in 36 different types of Italian healthcare facilities, were enrolled in this study. Age, treatment, tumor size (T), nodes (N), grade (G), estrogen receptor (ER) and progesterone receptor (PgR) status were prospectively collected in these CP patients. The same data were extracted from the main adjuvant trastuzumab RCTs and pooled using the random-effects model of DerSimonian and Laird. RCT and CP patients were compared by using the Cochran Q statistics. Results: Versus RCT patients, CP patients were more likely to be older than 50 years (65 vs. 49 %; p < 0.0001) and to have HR (ER and/or PgR)-positive (72 vs. 54 %; p < 0.0001) BC and less likely to have tumor >2 cm ( T ≥ 2 cm 39 vs. 59 %; p < 0.0001), positive N (47 vs. 89 %; p < 0.0001) and a high G (61 vs. 67 %; p = 0.0241). CP patients more frequently received adjuvant endocrine therapy (70 vs. 57 %; p < 0.0003) and less frequently adjuvant chemotherapy (97 vs. 99.7 %; p < 0.0001). Conclusions: Most tumor and clinical features differed significantly between CP and RCT patients. These data raise concerns about the applicability of RCT results to CP patients. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
9. Neoadjuvant Therapy in Breast Cancer.
- Author
-
Martincich, Laura, Bertotto, Ilaria, and Montemurro, Filippo
- Published
- 2012
- Full Text
- View/download PDF
10. Vertebral Augmentation with Nitinol Endoprosthesis: Clinical Experience in 40 Patients with 1-Year Follow-up.
- Author
-
Anselmetti, Giovanni, Manca, Antonio, Marcia, Stefano, Chiara, Gabriele, Marini, Stefano, Baroud, Gamal, Regge, Daniele, and Montemurro, Filippo
- Abstract
Purpose: This study was designed to assess the clinical outcomes of patients treated by vertebral augmentation with nitinol endoprosthesis (VNE) to treat painful vertebral compression fractures. Methods: Forty patients with one or more painful osteoporotic VCF, confirmed by MRI and accompanied by back-pain unresponsive to a minimum 2 months of conservative medical treatment, underwent VNE at 42 levels. Preoperative and postoperative pain measured with Visual Analog Scale (VAS), disability measured by Oswestry Disability Index (ODI), and vertebral height restoration (measured with 2-dimensional reconstruction CT) were compared at last follow-up (average follow-up 15 months). Cement extravasation, subsequent fractures, and implant migration were recorded. Results: Long-term follow-up was obtained in 38 of 40 patients. Both VAS and ODI significantly improved from a median of 8.0 (range 5-10) and 66 % (range 44-88 %) to 0.5 (range 0-8) and 6 % (range 6-66 %), respectively, at 1 year ( p < 0.0001). Vertebral height measurements comparing time points increased in a statistically significant manner (ANOVA, p < 0.001). Overall cement extravasation rate was 9.5 %. Discal and venous leakage rates were 7.1 and 0 % respectively. No symptomatic extravasations occurred. Five of 38 (13.1 %) patients experienced new spontaneous, osteoporotic fractures. No device change or migration was observed. Conclusions: VNE is a safe and effective procedure that is able to provide long-lasting pain relief and durable vertebral height gain with a low rate of new fractures and cement leakages. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
11. Omission of Axillary Dissection after a Positive Sentinel Node Dissection may Influence Adjuvant Chemotherapy Indications in Operable Breast Cancer Patients.
- Author
-
Montemurro, Filippo, Maggiorotto, Furio, Valabrega, Giorgio, Kubatzki, Franziska, Rossi, Valentina, Magistris, Alessandra, Marocco, Francesco, Gatti, Marco, Sarotto, Ivana, Aglietta, Massimo, and Ponzone, Riccardo
- Abstract
Background: This study was designed to evaluate how the omission of axillary dissection would have altered the indication for adjuvant chemotherapy (ACT) in patients with early breast cancer submitted to conservative surgery with one or two positive sentinel lymph nodes (SLNs). Methods: We identified 321 women in our institutional database who fulfilled the characteristics. All underwent completion axillary lymph node dissection (AD). Each case was blindly reviewed by our breast team in two rounds, and the total number of positive lymph nodes was disclosed only in the second. At each round, the panel chose between: (1) recommend, (2) discuss, (3) do not recommend ACT. Changes between round 1 and 2 were studied by the marginal homogeneity test. Exploratory logistic regression analyses were performed to study predictors of non-SLN involvement and of changes in the indication for ACT. Results: AD revealed non-SLNs metastases in 96 patients (30 %). Fifty-two patients (16 %) had their initial indication changed at round 2 ( p < 0.001). Most of the changes were toward ACT (83 %), and all except two occurred in patients with immunohistochemically defined luminal A and luminal B/HER2-negative tumors. In these two subgroups, a Ki67 above the median value (21 %) was the only independent predictor of no change in the indication to ACT at round 2. Conclusions: Omission of AD in patients with one or two positive SLNs may change the indication to ACT in a significant proportion of patients with hormone receptor-positive/HER2-negative tumors. All implications should be taken into account before abandoning AD, including a possible biologically tailored surgical approach. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
12. Correlations between diffusion-weighted imaging and breast cancer biomarkers.
- Author
-
Martincich, Laura, Deantoni, Veronica, Bertotto, Ilaria, Redana, Stefania, Kubatzki, Franziska, Sarotto, Ivana, Rossi, Valentina, Liotti, Michele, Ponzone, Riccardo, Aglietta, Massimo, Regge, Daniele, and Montemurro, Filippo
- Subjects
DIFFUSION magnetic resonance imaging ,BIOMARKERS ,BREAST cancer ,ESTROGEN receptors ,IMMUNOHISTOCHEMISTRY ,CONTRAST-enhanced magnetic resonance imaging - Abstract
Objective: We evaluated whether the apparent diffusion coefficient (ADC) provided by diffusion-weighted imaging (DWI) varies according to biological features in breast cancer. Methods: DWI was performed in 190 patients undergoing dynamic contrast-enhanced magnetic resonance imaging (MRI) for local staging. For each of the 192 index cancers we studied the correlation between ADC and classical histopathological and immunohistochemical breast tumour features (size, histological type, grade, oestrogen receptor [ER] and Ki-67 expression, HER2 status). ADC was compared with immunohistochemical surrogates of the intrinsic subtypes (Luminal A; Luminal B; HER2-enriched; triple-negative). Correlations were analysed using the Mann-Whitney U and Kruskal-Wallis H tests. Results: A weak, statistically significant correlation was observed between ADC values and the percentage of ER-positive cells (-0.168, P = 0.020). Median ADC values were significantly higher in ER-negative than in ER-positive tumours (1.110 vs 1.050 × 10 mm/s, P = 0.015). HER2-enriched tumours had the highest median ADC value (1.190 × 10 mm/s, range 0.950-2.090). Multiple comparisons showed that this value was significantly higher than that of Luminal A (1.025 × 10 mm/s [0.700-1.340], P = 0.004) and Luminal B/HER2-negative (1.060 × 10 mm/s [0.470-2.420], P = 0.008) tumours. A trend towards statistical significance ( P = 0.018) was seen with Luminal B/HER2-positive tumours. Conclusions: ADC values vary significantly according to biological tumour features, suggesting that cancer heterogeneity influences imaging parameters. Key Points: • DWI may identify biological heterogeneity of breast neoplasms. • ADC values vary significantly according to biological features of breast cancer. • Compared with other types, HER2-enriched tumours show highest median ADC value. • Knowledge of biological heterogeneity of breast neoplasm may improve imaging interpretation. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
13. Percutaneous Vertebroplasty in Multiple Myeloma: Prospective Long-Term Follow-Up in 106 Consecutive Patients.
- Author
-
Anselmetti, Giovanni, Manca, Antonio, Montemurro, Filippo, Hirsch, Joshua, Chiara, Gabriele, Grignani, Giovanni, Carnevale Schianca, Fabrizio, Capaldi, Antonio, Rota Scalabrini, Delia, Sardo, Elena, Debernardi, Felicino, Iussich, Gabriella, and Regge, Daniele
- Abstract
Purpose: Percutaneous vertebroplasty (PV) is a minimally invasive procedure involving the injection of bone cement within a collapsed vertebral body. Although this procedure was demonstrated to be effective in osteoporosis and metastases, few studies have been reported in cases of multiple myeloma (MM). We prospectively evaluated the safety and efficacy of PV in the treatment of vertebral compression fractures (VCFs) resulting from MM. Materials and Methods: PV was performed in 106 consecutive MM patients who had back pain due to VCFs, the treatment of which had failed conservative therapies. Follow-up (28.2 ± 12.1 months) was evaluated at 7 and 15 days as well as at 1, 3, 6, 12, 18, and every 6 months after PV. Visual analog scale (VAS) pain score, opioid use, external brace support, and Oswestry Disability Index (ODI) score were recorded. Results: The median pretreatment VAS score of 9 (range 4-10) significantly ( P < 0.001) decreased to 1 (range 0-9) after PV. Median pre-ODI values of 82% (range 36-89%) significantly improved to 7% (range 0-82%) ( P < 0.001). Differences in pretreatment and posttreatment use of analgesic drug were statistically significant ( P < 0.001). The majority of patients (70 of 81; 86%) did not use an external brace after PV ( P < 0.001). Conclusion: PV is a safe, effective, and long-lasting procedure for the treatment of vertebral compression pain resulting from MM. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
14. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
- Author
-
Valabrega, Giorgio, Capellero, Sonia, Cavalloni, Giuliana, Zaccarello, Gianluca, Petrelli, Annalisa, Migliardi, Giorgia, Milani, Andrea, Peraldo-Neia, Caterina, Gammaitoni, Loretta, Sapino, Anna, Pecchioni, Carla, Moggio, Aldo, Giordano, Silvia, Aglietta, Massimo, and Montemurro, Filippo
- Abstract
Trastuzumab has changed the prognosis of HER2 positive breast cancers. Despite this progress, resistance to trastuzumab occurs in most patients. Newer anti-HER2 therapies, like the dual tyrosine-kinase inhibitor (TKI) lapatinib, show significant antitumor activity, indicating that HER2 can be still exploited as a target after trastuzumab failure. However, since a high proportion of patients fail to respond to these alternative strategies, it is possible that cell escape from HER2 targeting may rely on HER2 independent pathways. The knowledge of these pathways deserve to be exploited to develop new therapies. We characterized two human HER2 overexpressing breast cancer cell lines resistant to trastuzumab and lapatinib (T100 and JIMT-1) from a molecular and biological point of view. Indeed, we assessed both in vitro and in vivo the activity of the multitarget inhibitor sorafenib. In both cell lines, the previously proposed mechanisms did not explain resistance to HER2 inhibitors. Notably, silencing HER2 by shRNA did not affect the growth of our cells, suggesting loss of reliance upon HER2. Moreover, we identified alterations in two antiapoptotic proteins Mcl-1 and Survivin which are known to be targets of the multikinase inhibitor sorafenib. Moreover, sorafenib, strongly inhibited the in vitro growth of T100 and JIMT-1 cells, through the downregulation of both Mcl-1 and Survivin. Similar results were obtained in JIMT-1 xenografts subcutaneously injected in NOD SCID mice. We provide preclinical evidence that tumor cells resistant to trastuzumab and lapatinib may rely on HER2 independent pathways that can be efficiently inhibited by sorafenib. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
15. Relationship between DCE-MRI morphological and functional features and histopathological characteristics of breast cancer.
- Author
-
Montemurro, Filippo, Martincich, Laura, Sarotto, Ivana, Bertotto, Ilaria, Ponzone, Riccardo, Cellini, Lisa, Redana, Stefania, Sismondi, Piero, Aglietta, Massimo, and Regge, Daniele
- Subjects
- *
MAGNETIC resonance imaging , *BREAST cancer , *CANCER patients , *BIOPSY , *LOGISTIC regression analysis , *HISTOPATHOLOGY - Abstract
We studied whether dynamic contrast-enhanced MRI (DCE-MRI) could identify histopathological characteristics of breast cancer. Seventy-five patients with breast cancer underwent DCE-MRI followed by core biopsy. DCE-MRI findings were evaluated following the scoring system published by Fischer in 1999. In this scoring system, five DCE-MRI features, three morphological (shape, margins, enhancement kinetic) and two functional (initial peak of signal intensity (SI) increase and behavior of signal intensity curve), are defined by 14 parameters. Each parameter is assigned points ranging from 0 to 1 or 0 to 2, with higher points for those that are more likely to be associated with malignancy. The sum of all the points defines the degree of suspicion of malignancy, with a score 0 representing the lowest and 8 the highest degree of suspicion. Associations between DCE-MRI features and tumor histopathological characteristics assessed on core biopsies (histological type, grading, estrogen and progesterone receptor status, Ki67 and HER2 status) were studied by contingency tables and logistic regression analysis. We found a significant inverse association between the Fischer's score and HER2-overexpression (odds ratio-OR 0.608, p = 0.02). Based on our results, we suggest that lesions with intermediate-low suspicious DCE-MRI parameters may represent a subset of tumor with poor histopathological characteristics. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
16. Dynamic contrast-enhanced MRI and sonography in patients receiving primary chemotherapy for breast cancer.
- Author
-
Montemurro, Filippo, Martincich, Laura, de Rosa, Giovanni, Cirillo, Stefano, Marra, Vincenzo, Biglia, Nicoletta, Gatti, Marco, Sismondi, Piero, Aglietta, Massimo, and Regge, Daniele
- Subjects
- *
BREAST cancer surgery , *DRUG therapy , *ULTRASONIC imaging , *CANCER patients , *MEDICAL imaging systems , *ANTINEOPLASTIC agents , *BREAST tumors , *COMPARATIVE studies , *DOXORUBICIN , *MAGNETIC resonance imaging , *RESEARCH methodology , *MEDICAL cooperation , *NONPARAMETRIC statistics , *PACLITAXEL , *RESEARCH , *TUMOR classification , *EVALUATION research , *CONTRAST media ,TUMOR surgery - Abstract
We compared dynamic contrast-enhanced MRI (DCE-MRI) and sonography (US) for monitoring tumour size in 21 patients with breast cancer undergoing primary chemotherapy (PCT) followed by surgery. The correlation between DCE-MRI and US measurements of tumour size, defined as the product of the two major diameters, was 0.555 (P=0.009), 0.782 (P<0.001), and 0.793 (P<0.001) at baseline, and after two and four cycles of PCT, respectively. The median tumour size was significantly larger when measured by DCE-MRI than by US at baseline (1472 vs 900 mm(2), P<0.001) and after two cycles of PCT (600 vs 400 mm(2), P=0.009). After PCT, the median tumour size measured by the two techniques was similar (256 vs 289 mm(2) for DCE-MRI and US, respectively, P=0.859). The correlation with the histopathological major tumour diameter was 0.824 (P<0.001) and 0.705 (P<0.001) for post-treatment DCE-MRI and US, respectively. Measurements of the final major tumour diameter by DCE-MRI tended to be more precise, including cases achieving a pathological complete response. Randomized trials are warranted to establish the clinical impact of the initial discrepancy in tumour size estimates between DCE-MRI and US, and the trend towards a better definition of the final tumour size provided by DCE-MRI in this clinical setting. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
17. TGFaexpression impairs Trastuzumab-induced HER2 downregulation.
- Author
-
Valabrega, Giorgio, Montemurro, Filippo, Sarotto, Ivana, Petrelli, Annalisa, Rubini, Patrizia, Tacchetti, Carlo, Aglietta, Massimo, Comoglio, Paolo Maria, and Giordano, Silvia
- Subjects
- *
CANCER treatment , *TRASTUZUMAB , *CELLS , *CLINICAL trials , *CELLULAR pathology , *CELL physiology - Abstract
The HER2 gene encodes a tyrosine kinase receptor overexpressed in 25-30%of human breast cancers. Clinical trials have shown the efficacy of the anti-HER2 monoclonal antibody Trastuzumab in metastatic breast cancer patients. Nevertheless, 70%of patients are unresponsive from start of treatment and nearly all become unresponsive during treatment. Possible mechanisms for these failures could depend on impairment of the machinery responsible for receptor downregulation. To test this hypothesis, we analysed the genomic sequences encoding regions known to be critical for HER2 downregulation, of both HER2 and of the ubiquitin ligase Cbl. We investigated 63 breast cancers, and found no mutations in these regions. We thus considered alternative mechanisms-such as TGFaproduction-possibly interfering with HER2 downregulation. In selected cases, by comparing breast cancer neoplastic tissue before and after Trastuzumab treatment, we found induction of TGFaexpression. Moreover, by in vitro expression of exogenous TGFain breast cancer cells, we observed a dramatic reduction in Trastuzumab-induced HER2 endocytosis, downregulation and cell growth inhibition. Our results suggest that unresponsiveness to Trastuzumab may not be due to intrinsic defects in the machinery responsible for HER2 downregulation, but can be associated with a TGFa-related mechanism of escape to HER2 downregulation.Oncogene (2005) 24, 3002-3010. doi:10.1038/sj.onc.1208478 Published online 14 February 2005 [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.